X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Edarbi-Generic (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) small molecule drug, which is indicated for the treatment of hypertension.
Lead Product(s): Azilsartan
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Edarbi-Generic
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 04, 2024
Details:
Through the license agreement, Dr. Reddy’s will receive semi-exclusive rights from Zydus to co-market Womab (pertuzumab) in India for the treatment of HER2-positive breast neoplasms.
Lead Product(s): Pertuzumab
Therapeutic Area: Oncology Product Name: Womab
Highest Development Status: Phase IVProduct Type: Large molecule
Partner/Sponsor/Collaborator: Dr. Reddy\\\'s Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 28, 2024
Details:
Edarbyclor-Generic is an angiotensin II receptor blocker (ARB) and a thiazide like diuretic combination product indicated for the treatment of hypertension.
Lead Product(s): Azilsartan,Chlorthalidone
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Edarbyclor-Generic
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2024
Details:
ZYIL1 (usnoflast) is an NLRP3 inhibitor, which is being evaluated in the mid-stage clinical trial studies with the patients for treating amyotrophic lateral sclerosis.
Lead Product(s): Usnoflast
Therapeutic Area: Neurology Product Name: ZYIL1
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2024
Details:
Theophylline generic extended-release tablets formulation approved for the use in the treatment of asthma and chronic obstructive pulmonary disease.
Lead Product(s): Theophylline
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Theo-Dur-Generic
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 22, 2024
Details:
Dexamethasone, a glucocorticoid receptor agonist, its generic version tablet form has been approved by USFDA for asthma and other inflammatory indications.
Lead Product(s): Dexamethasone
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Dexamethasone-Generic
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2024
Details:
Company' inactivated trivalent influenza vaccine has been recommended for additonal disease target approval in children above six months suffering from Influenza.
Lead Product(s): Inactivated Trivalent Influenza Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 08, 2024
Details:
Through the acquisition, Sentynl will commercialize the Zokinvy (lonafarnib) globally. It is the first and only treatment approved by the U.S. FDA to target the cause and symptoms of progeria, also known as Hutchinson-Gilford progeria syndrome.
Lead Product(s): Lonafarnib
Therapeutic Area: Genetic Disease Product Name: Zokinvy
Highest Development Status: Phase IVProduct Type: Small molecule
Recipient: Eiger BioPharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition May 03, 2024
Details:
Myrbetriq- Generic (mirabegron) is a beta-3 adrenergic receptor inhibitor which has been approved by FDA for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency.
Lead Product(s): Mirabegron
Therapeutic Area: Urology Product Name: Myrbetriq-Generic
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2024
Details:
NULIBRY (fosdenopterin) for Injection, the first therapy for the treatment of patients in Great Britain with molybdenum cofactor deficiency Type A, an ultra-rare, life-threatening genetic disorder that often progresses rapidly in infants.
Lead Product(s): Fosdenopterin
Therapeutic Area: Rare Diseases and Disorders Product Name: Nulibry
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
